Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Crizotinib-induced immunogenic cell death in non-small cell lung cancer.
Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G. Liu P, et al. Among authors: paci a. Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3. Nat Commun. 2019. PMID: 30940805 Free PMC article.
Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Paci A, Vassal G, Moshous D, Dalle JH, Bleyzac N, Neven B, Galambrun C, Kemmel V, Abdi ZD, Broutin S, Pétain A, Nguyen L. Paci A, et al. Ther Drug Monit. 2012 Apr;34(2):198-208. doi: 10.1097/FTD.0b013e31824c2f60. Ther Drug Monit. 2012. PMID: 22406655
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A. Pautier P, et al. Among authors: paci a. Oncoimmunology. 2013 Feb 1;2(2):e23079. doi: 10.4161/onci.23079. Oncoimmunology. 2013. PMID: 23525192 Free PMC article.
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.
Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C, Zitvogel L. Chaput N, et al. Among authors: paci a. Oncoimmunology. 2013 Feb 1;2(2):e23080. doi: 10.4161/onci.23080. Oncoimmunology. 2013. PMID: 23525357 Free PMC article.
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
Massicotte MH, Borget I, Broutin S, Baracos VE, Leboulleux S, Baudin E, Paci A, Deroussent A, Schlumberger M, Antoun S. Massicotte MH, et al. Among authors: paci a. J Clin Endocrinol Metab. 2013 Jun;98(6):2401-8. doi: 10.1210/jc.2013-1115. Epub 2013 Mar 29. J Clin Endocrinol Metab. 2013. PMID: 23543666 Clinical Trial.
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B. Bautista F, et al. Among authors: paci a. Pediatr Blood Cancer. 2014 Jun;61(6):1101-3. doi: 10.1002/pbc.24891. Epub 2013 Dec 3. Pediatr Blood Cancer. 2014. PMID: 24375920
319 results